ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.26% | +1.21% | +4.47% | +24.81% | +14.53% |
| Weighted Average Shares Diluted Growth | +0.26% | +1.21% | +4.47% | +24.81% | +14.53% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -42.29% | -32.67% | +1.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +68.57% | -34.27% | -12.74% | +11.56% | +21.18% |
| Book Value per Share Growth | +69.85% | -37.01% | -19.37% | -11.94% | +4.11% |
| Debt Growth | -44.48% | -51.58% | -60.80% | -84.14% | -92.05% |
| R&D Expense Growth | +0.76% | +261.05% | +27.28% | +60.13% | +59.57% |
| SG&A Expenses Growth | +13.96% | +48.23% | +50.63% | +48.38% | +87.69% |